CervoMed Inc.
CRVONext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for CRVO. That does not mean none is planned.
Get an email about CRVO's next catalysts
Track CervoMed (CRVO) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 2 past
No catalysts found.
Market Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Neflamapimod | Phase 2 | Moderate to Severe Acute Ischaemic Stroke | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in CervoMed Inc.'s drug pipeline?β
CatalystAlert tracks 1 drug candidate in CervoMed Inc.'s (CRVO) pipeline across Phase 2. Its lead program is Neflamapimod (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is CervoMed Inc.'s next FDA catalyst?β
CatalystAlert tracks every upcoming catalyst for CervoMed Inc. (CRVO) β PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings β each confidence-rated as confirmed, estimated or AI-detected.
How do I track CRVO biotech catalysts?β
Add CRVO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow CervoMed Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
